NCT00794586 - Study Evaluating Fosfomycin/Tobramycin for Inhalation in Cystic Fibrosis Patients With Pseudomonas Aeruginosa Lung Infection | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

February 28, 2010

Study Completion Date

March 31, 2010

Conditions

Cystic Fibrosis

Interventions

DRUG

FTI, AZLI

Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)

DRUG

Placebo, AZLI

Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).

Trial Locations (36)

10032

New York

11040

New Hyde Park

12208

Albany

13210

Syracuse

14222

Buffalo

17033

Hershey

19102

Philadelphia

20010

Washington D.C.

23298

Richmond

23708

Portsmouth

27599

Chapel Hill

29425

Charleston

32803

Orlando

33606

Tampa

43205

Columbus

44106

Cleveland

45229

Cincinnati

48109

Ann Arbor

48201

Detroit

60025

Glenview

60614

Chicago

72205

Little Rock

73112

Oklahoma City

77030

Houston

78212

San Antonio

80206

Denver

85016

Phoenix

85724

Tucson

89107

Las Vegas

94304

Palo Alto

98405

Tacoma

99508

Anchorage

06102

Hartford

06520

New Haven

02114

Boston

02115

Boston